Lilly Delays Diabetes Treatment Submission

Eli Lilly said it would hold off on submitting its late-stage diabetes treatment to both U.S. and European regulatory agencies for approval until it better understands the treatment’s potential side effects.



from WSJ.com: US Business http://ift.tt/1EIlLqO

via IFTTT